In this review:
- Continuing treat-to-target ULT for gout in remission
- Anifrolumab for Sjögren’s disease
- JAK inhibitor or anti-TNF for RA: patient choice
- Dietary fibre improves clinical response and Th17/Treg balance in RA
- GLP agonists: lower disease activity and pain in PsA, independent of weight change
- Quantitative nailfold videocapillaroscopy for assessing inflammatory myopathy activity
- Lupus nephritis histological activity and response linked to specific pathways
- Secukinumab in PMR
- Nipocalimab in SLE
- CD19 CAR T-cell therapy in active ACPA-positive, treatment-refractory RA
Please login below to download this issue (PDF)